CompletedNCT05461430
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Studying Adenocarcinoma of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Travera Inc
- Principal Investigator
- Mark Stevens, Phd, DMDTravera Inc
- Enrollment
- 72 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2028
Study locations (1)
- xCures, Oakland, California, United States
Collaborators
xCures
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05461430 on ClinicalTrials.govOther trials for Adenocarcinoma of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07523529Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid TumorsBeijing Biotech
- RECRUITINGNCT07100288Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian CancerComplejo Hospitalario Universitario Insular Materno Infantil
- RECRUITINGPHASE2NCT06730347A Study of Lorigerlimab in Participants With Advanced Solid TumorsMacroGenics
- RECRUITINGPHASE1NCT06840886A Study of PHST001 in Advanced Solid TumorsPheast Therapeutics
- RECRUITINGPHASE2NCT05500391Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote MonitoringCentre Oscar Lambret
- RECRUITINGPHASE1, PHASE2NCT05922930Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic CancerM.D. Anderson Cancer Center
- RECRUITINGPHASE3NCT05601700Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)Ente Ospedaliero Ospedali Galliera
- ACTIVE NOT RECRUITINGPHASE2NCT05335993A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.CanariaBio Inc.